Credit: Shutterly/Adobe Stock
No pharmacy therapeutic class has transformed plan sponsor's pharmacy benefits as much as GLP-1s in recent years.
What started two decades ago as a novel approach to controlling blood sugars for people with type 2 diabetes has now turned into one of the leading treatment strategies for promoting weight loss and reducing cardiovascular risk.
While these drugs have produced meaningful health benefits, they've also resulted in unprecedented demand and created cost-containment challenges that plan sponsors must address directly.
For many large employer plans, GLP-1s now account for more than 20% of their total pharmacy spend. With continual innovation by the drug manufacturers, including the introduction of an oral GLP-1 formulation for weight loss, plan sponsors must proactively define a strategy that balances between access, clinical value, and long-term financial viability.
The History
Over the years, GLP-1s have evolved through multiple stages of development.
Early versions helped people with type 2 diabetes control their blood sugar, but they required daily injections. They did not lead to weight loss.
Later, once-weekly injection options made treatment easier and delivered better results, improving both health outcomes and convenience for patients.
The real turning point happened when the makers of semaglutide (known as Ozempic and Wegovy) and tirzepatide (known as Mounjaro and Zepbound) demonstrated that people using those GLP-1s could lose more than 15% of their body weight. The drugs also reduced cardiovascular risk, even in patients without diabetes.
These results repositioned GLP-1s from being only treatments for diabetes into having a broader role in preventing obesity and supporting chronic health management. That expanded the number of people who could benefit from taking the drugs.
Given that, oral GLP-1s have been the next anticipated progression. The dream has been to offer a needle-free alternative aimed at making treatment easier for patients and, ideally, reducing costs, by letting patients use a less complex delivery system.
However, the first oral GLP-1 has not fully met those hopes and expectations.
New Option, Small Payoff
The 2019 FDA approval of oral semaglutide (Rybelsus) was an accomplishment, introducing a pill-based treatment for people with type 2 diabetes as an alternative to make it accessible and appealing.
Recommended dosing for Rybelsus is once-daily, versus the once-weekly injection schedule for Ozempic.
However, Rybelsus never gained the same traction as its injectable counterpart, Ozempic.
Studies also showed that Ozempic leads to better blood sugar control and weight-loss outcomes. At launch, Rybelsus didn't have the cardioprotective indication, potentially limiting its appeal to prescribers.
Rybelsus is priced similarly to the injectable option, and with less clinical benefit, the convenience of taking this oral form hasn't been compelling enough in the market to overtake the injectable form.
Oral Wegovy Changing Perspectives
In December 2025, the FDA approved oral semaglutide — a new version of Wegovy.
Unlike Rybelsus, oral Wegovy entered with an indication for weight loss. It also came with documented additional clinical benefits, supported by data demonstrating that its efficacy is similar to the efficacy of the popular injectable version.
Like Rybelsus, the oral form of Ozempic, oral Wegovy is also dosed once daily, versus once-weekly dosing for the injectable form.
The OASIS 4 trial demonstrated that adults who were overweight or obese and took the oral form of Wegovy lost an average of 16.6% of their body weight, which closely mirrored the average 17.4% reduction observed for the maintenance use of injectable Wegovy in the STEP 4 trial.
Oral Wegovy also demonstrated cardiovascular benefit, with the SOUL trial showing a 14% lower chance of experiencing serious cardiovascular events, giving an additional value beyond the weight-loss benefit alone.
In terms of cost, oral Wegovy is comparable to its injectable formulation, at a rough list price of $1,350 per 30 day supply.
Interestingly, the cash price offered directly by Novo Nordisk through the company's consumer website is considerably less for Wegovy versus its injectable counterpart, Ozempic.
On the direct-to-consumer platform, the oral Wegovy cash price is $149 to $299 monthly (for the low- and higher-dose forms), which is lower than the cash price for the low- and higher-dose injectable forms, which sits at $349 to $499 monthly.
Comparing Across the Drug Class
Oral Wegovy helps people lose a meaningful amount of weight and lowers cardiovascular risk, like its injectable version.
However, when compared with other options in its drug class, newer therapies like tirzepatide (Zepbound) have shown greater weight-loss benefits: more than 20% on average.
Gastrointestinal side effects remain the most common side effect across all of the GLP-1s, regardless of whether they're tablets or injectables.
Nausea, vomiting, diarrhea and constipation were the concerns most frequently reported, and they are the main reasons individuals need dose changes or stop taking the drugs altogether.
For both tirzepatide and semaglutide, dosing recommendations are to start with lower doses and titrate up to minimize potential side effects.
Not all patients need or can tolerate higher doses.
Plan Sponsor GLP-1 Coverage Landscape
Coverage of GLP-1s is expanding steadily.
An International Foundation of Employee Benefit Plans survey found that 36% of employers covered GLP-1s for both diabetes and weight loss in 2025. That was up from 34% in 2024.
Among employers not yet covering GLP-1s for weight loss, one in four say they're considering it, per a KFF study.
Since more people qualify for these drugs than are using them now, we may expect use to keep going up.
Even when coverage exists, strict utilization rules have often been applied by plan sponsors for weight-loss coverage.
Minimum requirements include meeting BMI thresholds. Some plans require documented participation and success in lifestyle intervention programs.
Major commercial carriers have also excluded weight-loss GLP-1s entirely.
For example, BCBS of Michigan removed coverage for Wegovy, Zepbound, and Saxenda for large-group members starting January 2025, because of a 29% jump in pharmacy spend.
Independence Blue Cross in Pennsylvania and others, including BCBS of Massachusetts, North Carolina's State Health Plan and large employers like Mayo Clinic and Ascension, have implemented comparable restrictions.
The Takeaway
With the arrival of oral Wegovy, employers may need to implement thoughtful guardrails, like tighter eligibility requirements, participation in lifestyle programs, and monitoring of member adherence to maintain coverage under the plan.
These steps can ensure the medications are used by the right patients, in the right way, and for long enough to produce meaningful results.
There are multiple ways plan sponsors can structure coverage, but doing so without a strategy increases financial risk.
The pipeline for oral GLP-1s continues to grow.
Newer medications, like orforglipron, which come to market this year, could increase competition and put downward pressure on prices over time.
Even then, strong utilization management will remain important, regardless of how drug prices change.
For plan sponsors, the challenge is to find the right balance.
Coverage decisions must align clinical evidence, the needs of the workforce, and long-term financial goals, especially in a drug class where plan cost exposure has proven to be high.
Renzo Luzzatti is president of US-Rx Care, a firm that provides fiduciary pharmacy risk management.
© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.